Primary Recommendation
RecommendedTrastuzumab + Pertuzumab + Chemotherapy
Predicted Efficacy
82%Resistance Risk
32% Low-ModerateTechnology Platform
Continuous oncology intelligence
Moving beyond static testing
Keti Flow replaces static testing with continuous, longitudinal oncology intelligence. Our platform tracks how individual breast, cervical and ovarian cancers change across time, therapies, and clinical decisions to predict drug resistance before clinical failure becomes visible.
See more →
The next generation of clinical decision support, combining longitudinal data modeling and real world outcome learning to predict, explain and bypass therapy resistance.
Alternative Option
AlternativePaclitaxel-based Chemotherapy
Predicted Efficacy
68%Resistance Risk
54% ModerateKeti Flow Platform Advantages
Monitor cancer evolution throughout the entire care timeline rather than relying on a single historic biopsy snapshot.
Recealing the exact pathway mutations, sub clonal expansions or adaptive signaling changes causing a therapy to stop working.
Instantly cross referencing active patients with similar historical profiles to forecast expected time to resistance.
Connecting clinical, molecular and historical outcomes to give oncology teams clear data driven treatment adjustments.
Traditional Diagnostic Tools
Relies on single biopsy snapshots or isolated genomic reports
Provides static laboratory or in vitro sensitivity results
Lacks context on how tumors adapt under therapy pressure
Reports clinical failure after it has already occurred
Offers a complex data readout with no clear explanation
Keti Flow Intelligence
Built on continuous, longitudinal patient monitoring
Utilizes time based, evolving disease modeling
Leverages real world treatment outcome learning
Delivers AI driven resistance predictions before scans change
Provides transparent, explainable clinical reasoning